Search Results - "Gilder, K"

The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy by Fujioka, K, Plodkowski, R, O'Neil, P M, Gilder, K, Walsh, B, Greenway, F L

“…Background/Objectives: Weight management medications increase the likelihood that patients will achieve clinically meaningful improvements in cardiovascular,…”
Get full text

Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion by Halseth, A., Shan, K., Gilder, K., Malone, M., Acevedo, L., Fujioka, K.

“…Summary Objective This multicenter, randomized, controlled, open‐label trial examined weight‐related quality of life, control over eating behaviour and sexual…”
Get full text

Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity by Kolotkin, R. L., Chen, S., Klassen, P., Gilder, K., Greenway, F. L.

“…Summary Weight loss is associated with improved quality of life in some, but not all, weight loss trials. We evaluated changes at 56 weeks in quality of life,…”
Get full text

519 POSTER A phase 2, single-arm study of volociximab (an anti-a5b1 integrin antibody) monotherapy in patients with platinum-resistant advanced epithelial ovarian cancer or primary peritoneal cancer by Matthews, C.M, Ho, S.N, Barve, M, Bell-McGuinn, K.M, Gilbert, L, Penson, R.T, Lengyel, E, Weymer, S, Gilder, K, Schilder, R.J

Get full text

P.750 Psychiatric- related safety of extended-release naltrexone/bupropion in combination with antidepressant therapy: Results from a large randomized controlled double-blind light trial by Blavignac, J., McIntyre S., R., McIntosh, D., Paron, E., Halseth, A., Gilder, K., Shan, K., Acevedo, L., Barakat, M.

Get full text

OP03 Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active Ulcerative Colitis: results from a randomised, double-blind, placebo-controlled, phase 2 trial by Sands, B E, Panaccione, R, D'Haens, G, Schreiber, S, DuVall, A, Kierkus, J, Naik, S, Gilder, K, Yun, C, Sandborn, W J, Walczak, M, Vermeire, S, Rubin, D T, Peyrin-Biroulet, L, Danese, S

“…Abstract Background VTX002 is a novel oral selective sphingosine-1-phosphate-1 (S1P1) receptor modulator in development for the treatment of ulcerative colitis…”
Get full text

P418 Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn’s disease by Higgins, P, Ginsburg, D, Gilder, K, Walsh, B, English, B, Turner, S, Klassen, P, Hanauer, S, Barish, C, Yacyshyn, B

“…Abstract Background Patients with Crohn’s disease (CD) often experience abdominal pain despite effective control of inflammation, contributing to opioid and…”
Get full text

P396 Pharmacokinetics and circulating total lymphocyte count pharmacodynamic response from single and multiple oral doses of etrasimod in Japanese and Caucasian healthy male subjects by Lee, C A, Acevedo, L, Oh, D A, Baweja, P, Gilder, K, Han, D, Jhee, S, Komori, K, Mullin, S, Nguyen-Cleary, T, Schmelzer, K, Tang, Y, Zhang, J, Grundy, J

“…Abstract Background Etrasimod is a selective, sphingosine 1-phosphate receptor modulator in development for chronic immune-mediated inflammatory disorders. We…”
Get full text

Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer by Vergote, I. B., Colombo, N., Kutarska, E., Del Campo, J., Pippitt, C., Casado, A., Lengyel, E., Gilder, K., Ho, S., Schilder, R. J.

“…Abstract only 5560 Background: Volociximab (V), a chimeric monoclonal antibody with direct antitumor effects, blocks α5β1 binding to fibronectin and induces…”
Get full text

IN MEMORIAM LALIAH B. PINGREE by GILDER, R. W.

Get full text